Affimed NV (LTS:0HL9)
$ 2.0799 -0.177 (-7.38%) Market Cap: 37.05 Mil Enterprise Value: 24.36 Mil PE Ratio: 0 PB Ratio: 1.94 GF Score: 32/100

Q1 2023 Affimed NV Earnings Call Transcript

May 23, 2023 / 12:30PM GMT
Release Date Price: $10.2 (-4.73%)
Operator

Good day, everyone, and welcome to Affimed's First Quarter 2023 Earnings and Corporate Update Call. (Operator Instructions) As a reminder, today's conference is being recorded.

I would now like to introduce your host for today's call, Alex Fudukidis, Head of Investor Relations at Affimed. Please go ahead.

Alexander Fudukidis
Affimed N.V. - Head of IR & Director of IR

Thank you, Liz, and thank you all for joining us today for our First Quarter 2023 Update Call.

Before we begin, I'd like to remind everyone that we issued 2 relevant press releases earlier today, which can be found on the Investor Relations section of our website.

On the call today, we have members of our management team, including Adi Hoess, our Chief Executive Officer; Andreas Harstrick, our Chief Medical Officer; Arndt Schottelius, our Chief Scientific Officer; Wolfgang Fischer, our Chief Operating Officer; Denise Mueller, our Chief Business Officer, and Angus Smith, our Chief Financial Officer. The team will be available for Q&A after the prepared remarks.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot